TN 201
Alternative Names: TN-201Latest Information Update: 16 Aug 2024
At a glance
- Originator Tenaya Therapeutics
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference; Myosin-binding protein C replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hypertrophic cardiomyopathy
Most Recent Events
- 08 Aug 2024 The US FDA grants the rare pediatric disease designation (RPDD) to TN 201 for the treatment of Hypertrophic Cardiomyopathy (In children, In adolescents, In adults)
- 31 Dec 2023 Tenaya Therapeutics has patent pending for TN 201 in USA and foreign countries, prior to December 2023
- 31 Dec 2023 Tenaya Therapeutics has patent protection for TN 201 in USA, prior to December 2023